Replies to post #7557 on GTC Biotherapeutics (fka GTCB)

[vinmantoo]

GTCB has stated that the data from 30 patients demonstrates that rATIII is non-inferior to plasma derived ATIII. They came to this conclusion without the need for the final patient. Therefore, we can assume that for the historical plasmid derived ATIII trials, there must have been at least 1 patient with clincial DVT. I would still liked to know how many there were now, but especially prior to the rATIII data release because if it was only 1, then I would have been far more nervous. If it was 2 or 3, I would have been more confident knowing that rATIII was already 0 out of 14 for clinical DVT from the European trial.